Hyderabad: City-based pharma giant Dr Reddy’s Laboratories (DRL) on Tuesday said the US drug watchdog United States Food and Drug Administration (USFDA), that re-audited its API manufacturing unit at Miryalaguda in Telangana, has issued a Form 483 with three observations. 

 The USFDA had inspected DRL’s Miryalaguda unit in January 2015, following which it had issued warning letter. In the meantime, DRL completed the remediation process at the unit and went for a USFDA re-audit of the unit. 
 
 “The audit of the company’s API manufacturing plant at Miryalaguda by the USFDA has been completed on February 21, 2017. The company has been issued a Form 483 with three observations, which the company is addressing,” DRL informed the bourses. n FDA Form 483 is issued to a firm’s management at the conclusion of an inspection if an investigator observes any conditions, that in their judgement may constitute violations of the Food Drug and Cosmetic (FD&C) Act and related Acts. Interestingly, in the case of the Miryalaguda unit, both USFDA and European drug regulators inspected the unit during the same period in January 2015. 
 
 
